This review shows that COVID-19 vaccination was generally linked to lower mortality, especially in older and high-risk groups, but that protection decreased over time and improved again after booster doses. Read the full paper to see where the evidence is strongest, which groups benefit most, and where important safety and interpretation questions remain.
Additional notes
This review includes one retracted publication (Reference 1). Why we kept it is explained on our social channels — share your view: https://x.com/i/status/2036173849289695527
Abstract: This paper aims to synthesize current evidence regarding the association between COVID-19 vaccination and mortality, evaluating vaccine effectiveness (VE) against COVID-19-specific death, all-cause mortality, and the influence of clinical comorbidities and waning immunity. The review utilises 966 original studies with 32894695 total participants (topic deduplicated ΣN). The evidence map strongly suggests that COVID-19 vaccination was associated with lower mortality across general populations, hospitalized cohorts, and many clinically vulnerable groups, with primary-series protection against COVID-19 death often reported in the 80-97% range and an estimated 19.8 million deaths averted globally in the first year of rollout. A recurrent pattern across the literature was waning of mortality protection after roughly 3-6 months, alongside restoration or enhancement of protection after booster doses, including fourth-dose and bivalent-booster benefit in older adults and long-term care populations. The mapped evidence also indicates that large surveillance studies did not show increased all-cause or cardiac-related mortality after vaccination, while rare fatal adverse syndromes such as vaccine-induced thrombotic thrombocytopenia remained uncommon but clinically important to recognize early. Clinically, these findings support continued prioritization of booster strategies for older adults, immunocompromised patients, and people with major comorbidity, while maintaining surveillance for rare serious adverse events and residual risk in frail populations. Because much of the evidence remains observational and vulnerable to healthy vaccinee and related biases, future research should focus on better-controlled comparative studies with standardized mortality outcomes and clearer evaluation of durability across variants, products, and high-risk subgroups.
Final search date and database lock: 2026-03-23 13:46:26 CET
Plan: Pro (expanded craft tokens; source: PubMed)
Source: PubMed
Total Abstracts/Papers: 3980
Downloaded Abstracts/Papers: 3980
Included original and non-original Abstracts/Papers (all): 1049
Included original Abstracts/Papers (Vote counting by direction of effect): 966
Reference Index (links used in paper): 179
Total participants (topic deduplicated ΣN): 32894695
Get access to the full paper
temporary link or permanent access.
The remaining part of the paper opens after purchase or unlock.
Reference Index (179)
[1] Increased Age-Adjusted Cancer Mortality After the Third mRNA-Lipid Nanoparticle Vaccine Dose During the COVID-19 Pandemic in Japan. — https://doi.org/10.7759/cureus.57860
[12] COVID-19 vaccination and all-cause and non-COVID-19 mortality. A revaluation of a study carried out in an Italian Province. — https://doi.org/10.19191/ep23.6.a643.075
[27] Effect of COVID-19 vaccination on mortality by COVID-19 and on mortality by other causes, the Netherlands, January 2021-January 2022. — https://doi.org/10.1016/j.vaccine.2023.06.005
[33] Risks of COVID-19-related hospitalisation and mortality among individuals with mental disorders following BNT162b2 and CoronaVac vaccinations: A case-control study. — https://doi.org/10.1016/j.psychres.2023.115515
[35] Long-term effectiveness of COVID-19 vaccines against infections, hospitalisations, and mortality in adults: findings from a rapid living systematic evidence synthesis and meta-analysis up to December, 2022. — https://doi.org/10.1016/s2213-2600(23)00015-2
[36] Humoral vaccine response and breakthrough infections in kidney transplant recipients during the COVID-19 pandemic: a nationwide cohort study. — https://doi.org/10.1016/j.eclinm.2023.102035
[43] Selection Effects and COVID-19 Mortality Risk after Pfizer vs. Moderna Vaccination: Evidence from Linked Mortality and Vaccination Records. — https://doi.org/10.3390/vaccines11050971
[50] COVID-19 Vaccination and Non-COVID-19 Mortality Risk - Seven Integrated Health Care Organizations, United States, December 14, 2020-July 31, 2021. — https://doi.org/10.15585/mmwr.mm7043e2
[54] Effectiveness of AstraZeneca vaccine against SARS-CoV-2 (ChAdox1-S) in reducing in-hospital mortality in individuals with COVID-19 and schizophrenia: A retrospective cohort study. — https://doi.org/10.1080/21645515.2024.2379865
[68] mRNA vaccine effectiveness against COVID-19-related hospitalisations and deaths in older adults: a cohort study based on data linkage of national health registries in Portugal, February to August 2021. — https://doi.org/10.2807/1560-7917.es.2021.26.38.2100833
[79] Does the healthy vaccinee bias rule them all? Association of COVID-19 vaccination status and all-cause mortality from an analysis of data from 2.2 million individual health records. — https://doi.org/10.1016/j.ijid.2024.02.019
[89] High vaccine effectiveness against coronavirus disease 2019 (COVID-19) and severe disease among residents and staff of long-term care facilities in Norway, November 2020-June 2021. — https://doi.org/10.1017/ash.2021.246
[108] Vaccine protection against COVID-19 mortality in relation to time since last booster dose among nursing home residents in Sweden - A case-control study over 35 months. — https://doi.org/10.1016/j.vaccine.2025.128043
[122] Clinical characteristics and outcomes of critically ill patients with one, two and three doses of vaccination against COVID-19 in Australia. — https://doi.org/10.1111/imj.15884
[124] Demographic Characteristics and Status of Vaccinated Individuals with a History of COVID-19 Infection Pre- or Post-Vaccination: A Descriptive Study of a Nationally Representative Sample in Saudi Arabia. — https://doi.org/10.3390/vaccines10020323
[128] Comparative Analysis of Mortality From Coronavirus Disease 2019 Across the European Union Countries and the Effects of Vaccine Coverage. — https://doi.org/10.1093/ofid/ofac006
[133] Interrupting vaccination policies can greatly spread SARS-CoV-2 and enhance mortality from COVID-19 disease: The AstraZeneca case for France and Italy. — https://doi.org/10.1063/5.0050887
[134] The Effect of a Booster Dose mRNA Vaccine on COVID-19 Infection in Kidney Transplant Recipients after Inactivated or Viral Vector Vaccine Immunization. — https://doi.org/10.3390/vaccines10101690
[145] The causes of Australian excess deaths in 2021, and beyond: An ecological study considering COVID-19, the lockdowns, and the vaccines. — https://doi.org/10.1177/09246479261426743
[174] The Mirror of Erised: a retrospective population-wide study of Czech all-cause mortality data by COVID-19 vaccination status. — https://doi.org/10.1186/s12889-025-23619-x
[184] Pfizer-BioNTech vaccine effectiveness against Sars-Cov-2 infection: Findings from a large observational study in Israel. — https://doi.org/10.1016/j.ypmed.2021.106947
[204] COVID-19 vaccine-associated myocarditis: Analysis of the suspected cases reported to the EudraVigilance and a systematic review of the published literature. — https://doi.org/10.1016/j.ijcha.2023.101280
[211] Effectiveness and durability of a second COVID-19 booster against severe outcomes among older people in Norway: a population-based cohort study comparing mono- and bivalent booster doses. — https://doi.org/10.1093/ije/dyad114
[217] High Anti-CoV2S Antibody Levels at Hospitalization Are Associated with Improved Survival in Patients with COVID-19 Vaccine Breakthrough Infection. — https://doi.org/10.3390/ijerph192315581
[221] Effectiveness of bivalent mRNA booster vaccination and previous infection in older adults during Omicron period: real-world evidence. — https://doi.org/10.1093/ageing/afae251
[224] Effectiveness of the First and Second Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine Dose: A Nationwide Cohort Study From Austria on Hybrid Versus Natural Immunity. — https://doi.org/10.1093/ofid/ofae547
[231] COVID-19 vaccine effectiveness against hospitalisation and death of people in clinical risk groups during the Delta variant period: English primary care network cohort study. — https://doi.org/10.1016/j.jinf.2023.08.005
[239] Risk of death and cardiovascular events following COVID-19 vaccination or positive SARS-CoV-2 test amongst adult Singaporeans during omicron transmission. — https://doi.org/10.1016/j.vaccine.2024.126356
[270] Ethnic differences in COVID-19 mortality in the second and third waves of the pandemic in England during the vaccine rollout: a retrospective, population-based cohort study. — https://doi.org/10.1186/s12916-022-02704-7
[288] Vaccine Induced Immune Thrombotic Thrombocytopenia Causing a Severe Form of Cerebral Venous Thrombosis With High Fatality Rate: A Case Series. — https://doi.org/10.3389/fneur.2021.721146
[294] Real-world effectiveness of COVID-19 vaccination in liver cirrhosis: a systematic review with meta-analysis of 51,834 patients. — https://doi.org/10.1080/08998280.2023.2165344
[306] The unintended consequences of COVID-19 vaccine policy: why mandates, passports and restrictions may cause more harm than good. — https://doi.org/10.1136/bmjgh-2022-008684
[330] Outcomes of vaccinated versus unvaccinated COVID-19 patients in Israel during the Omicron and Delta waves-A retrospective cohort study. — https://doi.org/10.1016/j.medcli.2023.04.003
[331] Real-life outcomes of COVID-19 vaccination in kidney transplant patients: a single-center experience. — https://doi.org/10.3855/jidc.17956
[332] The effectiveness of COVID-19 vaccination against all-cause mortality in patients with type 2 diabetes mellitus: The observation during the initial period of the cancellation of the "Dynamic Zero Policy" in mainland China. — https://doi.org/10.1016/j.diabres.2023.110694
[334] Breakthrough COVID-19 in vaccinated patients with hematologic malignancies: results from the EPICOVIDEHA survey. — https://doi.org/10.1182/blood.2022017257
[335] COVID-19 vaccination outcomes in patients with a solid malignancy: Insights from extensive real-world data and propensity score matched analyses. — https://doi.org/10.1016/j.ajic.2023.12.015
[352] Prevalence and risk factors of COVID-19 infection, mortality, and post-infection lung fibrosis in patients with type 2 diabetes: a cross-sectional study. — https://doi.org/10.1177/03000605231198413
[357] Response to and outcomes of the Pfizer BNT162B2 vaccine in hemodialysis patients-A prospective observational study. — https://doi.org/10.1111/hdi.13005
[366] The Effectiveness of COVID-19 Vaccines in Improving the Outcomes of Hospitalized COVID-19 Patients. — https://doi.org/10.7759/cureus.21485
[388] Impact of vaccination against severe COVID-19 in the French population aged 50 years and above: a retrospective population-based study. — https://doi.org/10.1186/s12916-023-03119-8
[392] A prospective observational cohort study of covid-19 epidemiology and vaccine seroconversion in South Western Sydney, Australia, during the 2021-2022 pandemic period. — https://doi.org/10.1186/s12882-024-03560-8
[418] Effectiveness of mRNA and viral-vector vaccines in epidemic period led by different SARS-CoV-2 variants: A systematic review and meta-analysis. — https://doi.org/10.1002/jmv.28623
[422] Analysis of the Association Between BNT162b2 mRNA COVID-19 Vaccination and Deaths Within 10 Days After Vaccination Using the Sex Ratio in Japan. — https://doi.org/10.7759/cureus.50144
[424] Beyond prevention: Unveiling the benefits of triple vaccination on COVID-19 severity and resource utilization in solid organ transplant recipients. — https://doi.org/10.1016/j.trim.2024.102048
[430] Effectiveness of mRNA COVID-19 vaccines in preventing SARS-CoV-2 infections and COVID-19 hospitalisations and deaths in elderly long-term care facility residents, Spain, weeks 53 2020 to 13 2021. — https://doi.org/10.2807/1560-7917.es.2021.26.24.2100452
[432] Effectiveness of BNT162b2 and CoronaVac vaccinations against SARS-CoV-2 omicron infection in people aged 60 years or above: a case-control study. — https://doi.org/10.1093/jtm/taac119
[437] Effectiveness of mRNA-1273, BNT162b2, and BBIBP-CorV vaccines against infection and mortality in children in Argentina, during predominance of delta and omicron covid-19 variants: test negative, case-control study. — https://doi.org/10.1136/bmj-2022-073070
[438] Effect of pre-hospitalization use of oral antiviral agents on reducing critical illness and mortality for patients with COVID-19 pneumonia. — https://doi.org/10.1016/j.ijantimicag.2023.107020
[452] Estimated Deaths Averted in Adults by COVID-19 Vaccination in Select Latin American and Caribbean Countries. — https://doi.org/10.1093/ofid/ofae528
[461] Effectiveness of the BNT162b2 vaccine in preventing morbidity and mortality associated with COVID-19 in children aged 5 to 11 years: A systematic review and meta-analysis. — https://doi.org/10.1371/journal.pgph.0002676
[470] Effectiveness of a Second COVID-19 Vaccine Booster Dose Against Infection, Hospitalization, or Death Among Nursing Home Residents - 19 States, March 29-July 25, 2022. — https://doi.org/10.15585/mmwr.mm7139a2
[472] Area-related sociodemographic factors and the risk of severe COVID-19: a longitudinal study of the total adult population in Sweden. — https://doi.org/10.1080/23744235.2025.2503466
[477] Quantifying the Population-Level Effect of the COVID-19 Mass Vaccination Campaign in Israel: A Modeling Study. — https://doi.org/10.1093/ofid/ofac087
[480] Effectiveness and Respiratory Adverse Events Following Inactivated and mRNA COVID-19 Vaccines in Patients with COPD and Asthma: A Chinese Population-Based Study. — https://doi.org/10.1007/s40264-023-01364-7
[483] Prospective clinical surveillance for severe acute respiratory illness and COVID-19 vaccine effectiveness in Kenyan hospitals during the COVID-19 pandemic. — https://doi.org/10.1186/s12879-024-10140-6
[485] Low antispike antibody levels correlate with poor outcomes in COVID-19 breakthrough hospitalizations. — https://doi.org/10.1111/joim.13471
[488] Impact of vaccination against the novel coronavirus infection (COVID-19) with Sputnik V on mortality during the delta variant surge. — https://doi.org/10.1016/j.jiph.2023.04.008
[494] Effectiveness and waning of protection with the BNT162b2 vaccine against the SARS-CoV-2 Delta variant in immunocompromised individuals. — https://doi.org/10.3389/fimmu.2023.1247129
[496] Differences in characteristics and outcomes of older patients hospitalized for COVID-19 after introduction of vaccination. — https://doi.org/10.1007/s41999-024-01002-0
[502] Epidemiology of COVID-19 outbreaks in aged care facilities during postvaccine period: a systematic review and meta-analysis. — https://doi.org/10.1136/bmjopen-2023-073555
[508] COVID-19 Vaccines Confer Protection in Hospitalized Pregnant and Postpartum Women with Severe COVID-19: A Retrospective Cohort Study. — https://doi.org/10.3390/vaccines10050749
[509] Investigating mortality trends in Italy during the COVID-19 pandemic: life expectancy changes within provinces and vaccination campaign impact up to December 2022. — https://doi.org/10.1016/j.puhe.2023.09.031
[526] IDSA 2025 Guidelines on the use of vaccines for the prevention of seasonal COVID-19 infections in immunocompromised patients. — https://doi.org/10.1093/cid/ciag115
[534] Effectiveness of BNT162b2 and CoronaVac against COVID-19-related severe outcomes among children and adolescents: A Brazilian nationwide cohort study. — https://doi.org/10.1016/j.vaccine.2024.126550
[553] Health Care System Overstretch and In-Hospital Mortality of Intubated Patients With COVID-19 in Greece From September 2020 to April 2022: Updated Retrospective Cohort Study. — https://doi.org/10.2196/43341
[558] Effectiveness of SARS-CoV-2 primary vaccines and boosters in patients with type 2 diabetes mellitus in Hungary (HUN-VE 4 Study). — https://doi.org/10.1136/bmjdrc-2023-003777
[564] Comparison of immunogenicity and clinical effectiveness between BNT162b2 and ChAdOx1 SARS-CoV-2 vaccines in people with end-stage kidney disease receiving haemodialysis: A prospective, observational cohort study. — https://doi.org/10.1016/j.lanepe.2022.100478
[570] Impact of prior vaccination with Covishield and Covaxin® on mortality among symptomatic COVID-19 patients during the second wave of the pandemic in South India during April and May 2021: a cohort study. — https://doi.org/10.1016/j.vaccine.2022.02.023
[584] Increasing insight in the value of repetitive COVID-19 vaccination in patients with haematological malignancies in the Omicron era. — https://doi.org/10.1111/bjh.19221
[604] Post-Vaccination Coronavirus Disease 2019: A Case-Control Study and Genomic Analysis of 119 Breakthrough Infections in Partially Vaccinated Individuals. — https://doi.org/10.1093/cid/ciab714
[605] Unmeasured confounding and misclassification in studies estimating vaccine effectiveness against hospitalisation and death using electronic health records (EHRs): an evaluation of a multi-country European retrospective cohort study. — https://doi.org/10.1186/s12874-025-02742-8
[625] Insufficient response to mRNA SARS-CoV-2 vaccine and high incidence of severe COVID-19 in kidney transplant recipients during pandemic. — https://doi.org/10.1111/ajt.16902
[633] Effectiveness of successive booster vaccine doses against SARS-CoV-2 related mortality in residents of long-term care facilities in the VIVALDI study. — https://doi.org/10.1093/ageing/afad141
[640] Multimorbidity and Frailty Are the Key Characteristics of Patients Hospitalized with COVID-19 Breakthrough Infection during Delta Variant Predominance in Italy: A Retrospective Study. — https://doi.org/10.3390/jcm11185442
[642] Effectiveness of mRNA COVID-19 Vaccine Boosters Against Infection, Hospitalization, and Death: A Target Trial Emulation in the Omicron (B.1.1.529) Variant Era. — https://doi.org/10.7326/m22-1856
[645] Outcome of COVID-19 infection and the impact of COVID-19 vaccination in chronic kidney disease patients: A single-center study. — https://doi.org/10.4103/aam.aam_81_22
[678] Clinical Post-SARS-CoV-2 Infection Scenarios in Vaccinated and Non-Vaccinated Cancer Patients in Three German Cancer Centers: A Retrospective Analysis. — https://doi.org/10.3390/cancers14153746
[688] COVID-19 Incidence and Mortality Among Unvaccinated and Vaccinated Persons Aged ≥12 Years by Receipt of Bivalent Booster Doses and Time Since Vaccination - 24 U.S. Jurisdictions, October 3, 2021-December 24, 2022. — https://doi.org/10.15585/mmwr.mm7206a3
[690] Comparing the Impact of COVID-19 on Vaccinated and Unvaccinated Patients Affected by Myasthenia Gravis. — https://doi.org/10.3390/life13041064
[696] Estimated number of lives directly saved by COVID-19 vaccination programmes in the WHO European Region from December, 2020, to March, 2023: a retrospective surveillance study. — https://doi.org/10.1016/s2213-2600(24)00179-6
[702] Effectiveness of a second BNT162b2 booster vaccine against hospitalization and death from COVID-19 in adults aged over 60 years. — https://doi.org/10.1038/s41591-022-01832-0
[712] Pregnancy outcomes and vaccine effectiveness during the period of omicron as the variant of concern, INTERCOVID-2022: a multinational, observational study. — https://doi.org/10.1016/s0140-6736(22)02467-9
[713] Thrombosis and Bleeding in Patients with Vaccine-Induced Immune Thrombotic Thrombocytopenia: A Systematic Review of Published Cases. — https://doi.org/10.1055/s-0043-1777134
[721] Comprehensive statistical analysis reveals significant benefits of COVID-19 vaccination in hospitalized patients: propensity score, covariate adjustment, and feature importance by permutation. — https://doi.org/10.1186/s12879-024-09865-1
[723] The Relationship of Vaccine Uptake and COVID-19 Infections Among Nursing Home Staff and Residents in Missouri: A Measure of Risk by Community Mobility. — https://doi.org/10.1097/phh.0000000000001824
[726] Immune Cell Response during COVID-19 Infection and following SARS-CoV-2 Vaccination in Patients Admitted to Intensive Care Unit. — https://doi.org/10.1155/2023/4059484
[762] [Morbidity and mortality in hospitalised patients vaccinated versus hospitalised patients not vaccinated against COVID-19 in three regions of Cameroon]. — https://doi.org/10.11604/pamj.2024.48.114.40348
[767] Two-dose ChAdOx1 nCoV-19 vaccine protection against COVID-19 hospital admissions and deaths over time: a retrospective, population-based cohort study in Scotland and Brazil. — https://doi.org/10.1016/s0140-6736(21)02754-9
[779] Characteristics and clinical outcomes of patients with pre-delta, delta and omicron SARS-CoV-2 infection in Indonesia (2020-2023): a multicentre prospective cohort study. — https://doi.org/10.1016/j.lansea.2023.100348
[781] Impact of vaccination on hospitalization and mortality from COVID-19 in patients with primary and secondary immunodeficiency: The United Kingdom experience. — https://doi.org/10.3389/fimmu.2022.984376
[782] A quantitative evaluation of the impact of vaccine roll-out rate and coverage on reducing deaths: insights from the first 2 years of COVID-19 epidemic in Iran. — https://doi.org/10.1186/s12916-023-03127-8
[788] Direct and indirect impact of the COVID-19 pandemic on the survival of kidney transplant recipients: A national observational study in France. — https://doi.org/10.1016/j.ajt.2023.10.017
[804] Outcome of early treatment of SARS-CoV-2 infection in patients with haematological disorders. — https://doi.org/10.1111/bjh.18690
[805] Understanding the change of in-hospital mortality and respiratory failure between Delta and Omicron waves from a tertiary hospital in Southern Thailand: A retrospective cohort study. — https://doi.org/10.1016/j.ijregi.2024.100446
[857] Characteristics and Outcomes of Patients With Cerebral Venous Sinus Thrombosis in SARS-CoV-2 Vaccine-Induced Immune Thrombotic Thrombocytopenia. — https://doi.org/10.1001/jamaneurol.2021.3619
[859] Risk prediction of covid-19 related death and hospital admission in adults after covid-19 vaccination: national prospective cohort study. — https://doi.org/10.1136/bmj.n2244
[876] A post-marketing safety assessment of COVID-19 mRNA vaccination for serious adverse outcomes using administrative claims data linked with vaccination registry in a city of Japan. — https://doi.org/10.1016/j.vaccine.2022.10.088
[880] The effect of COVID-19 mRNA vaccines against postvaccination laboratory-confirmed SARS-CoV-2 infection, symptomatic COVID-19 infection, hospitalization, and mortality rate: a systematic review and meta-analysis. — https://doi.org/10.1080/14760584.2022.2102001
[882] Breakthrough SARS-CoV-2 infections among patients with cancer following two and three doses of COVID-19 mRNA vaccines: a retrospective observational study from the COVID-19 and Cancer Consortium. — https://doi.org/10.1016/j.lana.2023.100445
[898] Association of BNT162b2 Vaccine Third Dose Receipt With Incidence of SARS-CoV-2 Infection, COVID-19-Related Hospitalization, and Death Among Residents of Long-term Care Facilities, August to October 2021. — https://doi.org/10.1001/jamanetworkopen.2022.19940
[908] Impact of COVID-19 on immunocompromised populations during the Omicron era: insights from the observational population-based INFORM study. — https://doi.org/10.1016/j.lanepe.2023.100747
[911] Immunogenicity and safety of adjuvant-associated COVID-19 vaccines: A systematic review and meta-analysis of randomized controlled trials. — https://doi.org/10.1016/j.heliyon.2023.e22858
[926] Association of Primary and Booster Vaccination and Prior Infection With SARS-CoV-2 Infection and Severe COVID-19 Outcomes. — https://doi.org/10.1001/jama.2022.17876
[938] Risk of Worsening Heart Failure and All-Cause Mortality Following COVID-19 Vaccination in Patients With Heart Failure: A Nationwide Real-World Safety Study. — https://doi.org/10.1161/circheartfailure.123.010617
[958] Comparative effectiveness of two- and three-dose COVID-19 vaccination schedules involving AZD1222 and BNT162b2 in people with kidney disease: a linked OpenSAFELY and UK Renal Registry cohort study. — https://doi.org/10.1016/j.lanepe.2023.100636
[959] Impact of COVID-19 on Psychiatric Patients: The Role of Vaccination, Comorbidities, and Biomarkers in Clinical Outcomes. — https://doi.org/10.3390/jcm13195950
[964] Effectiveness of CoronaVac, ChAdOx1 nCoV-19, BNT162b2, and Ad26.COV2.S among individuals with previous SARS-CoV-2 infection in Brazil: a test-negative, case-control study. — https://doi.org/10.1016/s1473-3099(22)00140-2
[967] Clinical Manifestations and Adverse Cardiovascular Events in Patients with Cardiovascular Symptoms after mRNA Coronavirus Disease 2019 Vaccines. — https://doi.org/10.3349/ymj.2023.0354
[985] Tixagevimab/cilgavimab for preventing COVID-19 during the Omicron surge: retrospective analysis of National Veterans Health Administration electronic data. — https://doi.org/10.1128/mbio.01024-23
[992] Omicron variant dominance and anti-SARS-CoV-2 vaccination are key determinants for a milder course of COVID-19 in patients with systemic autoimmune rheumatic diseases. — https://doi.org/10.1007/s10067-023-06769-4
[995] Pandemic Phase-Adjusted Analysis of COVID-19 Outcomes Reveals Reduced Intrinsic Vulnerability and Substantial Vaccine Protection From Severe Acute Respiratory Syndrome Coronavirus 2 in Patients With Breast Cancer. — https://doi.org/10.1200/jco.22.01667
[1022] Adverse outcomes of SARS-CoV-2 infection with delta and omicron variants in vaccinated versus unvaccinated US veterans: retrospective cohort study. — https://doi.org/10.1136/bmj-2022-074521
[1024] Vaccination against coronavirus disease 2019 in patients with pulmonary hypertension: A national prospective cohort study. — https://doi.org/10.1097/cm9.0000000000002767
[1027] Association of COVID-19 Vaccination With Risk of COVID-19 Infection, Hospitalization, and Death in Heart Transplant Recipients. — https://doi.org/10.1001/jamacardio.2022.0670
[1038] Cerebral Venous Sinus Thrombosis and Thrombotic Events After Vector-Based COVID-19 Vaccines: A Systematic Review and Meta-analysis. — https://doi.org/10.1212/wnl.0000000000012896
